BOSTON–(BUSINESS WIRE)– #ANXIETY–Quolet, a private clinical stage biopharmaceutical company, is announcing the completion of a Phase 1 healthy volunteer study evaluating pure Cannabidiol (CBD) (clinicaltrials.gov NCT05032807). CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. However, oral CBD has relatively poor bioavailability. Researchers at King’s College London partnered wit
Source link
